PE20061245A1 - Composiciones para la transmision transmucosa oral de la metformina - Google Patents

Composiciones para la transmision transmucosa oral de la metformina

Info

Publication number
PE20061245A1
PE20061245A1 PE2006000346A PE2006000346A PE20061245A1 PE 20061245 A1 PE20061245 A1 PE 20061245A1 PE 2006000346 A PE2006000346 A PE 2006000346A PE 2006000346 A PE2006000346 A PE 2006000346A PE 20061245 A1 PE20061245 A1 PE 20061245A1
Authority
PE
Peru
Prior art keywords
metformin
acidonic
oral
pharmaceutical agent
transmucous
Prior art date
Application number
PE2006000346A
Other languages
English (en)
Spanish (es)
Inventor
Anna E Gluskin
Qazi Muhammad Waseem T
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of PE20061245A1 publication Critical patent/PE20061245A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2006000346A 2005-03-30 2006-03-29 Composiciones para la transmision transmucosa oral de la metformina PE20061245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30

Publications (1)

Publication Number Publication Date
PE20061245A1 true PE20061245A1 (es) 2007-01-06

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000346A PE20061245A1 (es) 2005-03-30 2006-03-29 Composiciones para la transmision transmucosa oral de la metformina

Country Status (16)

Country Link
US (1) US20090069437A1 (enExample)
EP (1) EP1863465A4 (enExample)
JP (1) JP2008534523A (enExample)
AR (1) AR052960A1 (enExample)
AU (1) AU2006228949A1 (enExample)
BR (1) BRPI0611555A2 (enExample)
CA (1) CA2603450A1 (enExample)
CR (1) CR9363A (enExample)
IL (1) IL185931A0 (enExample)
MX (1) MX2007012047A (enExample)
NZ (1) NZ560990A (enExample)
PE (1) PE20061245A1 (enExample)
RU (2) RU2409357C2 (enExample)
UY (1) UY29445A1 (enExample)
WO (1) WO2006102752A1 (enExample)
ZA (1) ZA200708834B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
US20100286200A1 (en) * 2008-01-16 2010-11-11 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP2445494A4 (en) * 2009-06-24 2012-12-12 Univ Koebenhavn TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
WO2020227344A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
DE69918105T2 (de) * 1998-04-29 2005-07-07 Sumitomo Pharmaceuticals Co., Ltd. Orale zubereitung enthaltend einen biguanid und eine organische säure
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
BR0115390A (pt) * 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
KR20120034211A (ko) * 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2005041925A2 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption

Also Published As

Publication number Publication date
WO2006102752A1 (en) 2006-10-05
NZ560990A (en) 2009-02-28
RU2007139886A (ru) 2009-05-10
US20090069437A1 (en) 2009-03-12
MX2007012047A (es) 2007-12-12
ZA200708834B (en) 2008-11-26
AR052960A1 (es) 2007-04-11
CR9363A (es) 2008-02-12
EP1863465A4 (en) 2010-12-15
EP1863465A1 (en) 2007-12-12
RU2010139163A (ru) 2012-03-27
JP2008534523A (ja) 2008-08-28
CA2603450A1 (en) 2006-10-05
RU2409357C2 (ru) 2011-01-20
BRPI0611555A2 (pt) 2010-09-21
IL185931A0 (en) 2008-02-09
UY29445A1 (es) 2006-10-02
AU2006228949A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
PE20080698A1 (es) Composiciones farmaceuticas de inhibidores de dpp iv
CO6270215A2 (es) Trans-clomifeno para el sindrome metabolico
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
AR050418A1 (es) Dosificacion fija de anticuerpos her
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
PE20060002A1 (es) Combinaciones antineoplasicas de cci-779 y rituximab
UY32503A (es) Formulación pesticida de uso agrícola a base de avermectina y un agente fotoprotector
ECSP088240A (es) Composición de trazodona para administración una vez por día
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
RU2013110003A (ru) Комбинация соединений для лечения или предотвращения кожных заболеваний
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
MX2009004692A (es) Composicion para el tratamiento de afecciones de la piel.
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
EP2392322A3 (en) Dosing regimes for trans-clomiphene
CU20070094A7 (es) Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
DE602004018647D1 (de) Galloylpeptide

Legal Events

Date Code Title Description
FC Refusal